GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (NAS:IBRX) » Definitions » EV-to-EBIT

ImmunityBio (ImmunityBio) EV-to-EBIT : -13.31 (As of May. 08, 2024)


View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ImmunityBio's Enterprise Value is $6,052.58 Mil. ImmunityBio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-454.71 Mil. Therefore, ImmunityBio's EV-to-EBIT for today is -13.31.

The historical rank and industry rank for ImmunityBio's EV-to-EBIT or its related term are showing as below:

IBRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -63.58   Med: -7.45   Max: -3.22
Current: -13.3

During the past 5 years, the highest EV-to-EBIT of ImmunityBio was -3.22. The lowest was -63.58. And the median was -7.45.

IBRX's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.54 vs IBRX: -13.30

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. ImmunityBio's Enterprise Value for the quarter that ended in Dec. 2023 was $3,829.06 Mil. ImmunityBio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-454.71 Mil. ImmunityBio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -11.88%.


ImmunityBio EV-to-EBIT Historical Data

The historical data trend for ImmunityBio's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio EV-to-EBIT Chart

ImmunityBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -8.20 -7.78 -8.42

ImmunityBio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.78 -4.24 -5.44 -4.97 -8.42

Competitive Comparison of ImmunityBio's EV-to-EBIT

For the Biotechnology subindustry, ImmunityBio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmunityBio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunityBio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ImmunityBio's EV-to-EBIT falls into.



ImmunityBio EV-to-EBIT Calculation

ImmunityBio's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=6052.582/-454.714
=-13.31

ImmunityBio's current Enterprise Value is $6,052.58 Mil.
ImmunityBio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-454.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ImmunityBio  (NAS:IBRX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

ImmunityBio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-454.714/3829.06334
=-11.88 %

ImmunityBio's Enterprise Value for the quarter that ended in Dec. 2023 was $3,829.06 Mil.
ImmunityBio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-454.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ImmunityBio EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of ImmunityBio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmunityBio (ImmunityBio) Business Description

Traded in Other Exchanges
Address
3530 John Hopkins Court, San Diego, CA, USA, 92121
ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. Geographically, the company operates in United States and Europe. Majority of the revenue is generated from Europe.
Executives
Patrick Soon-shiong director, 10 percent owner, officer: See remarks 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
California Capital Equity, Llc 10 percent owner 10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Cambridge Equities, Lp 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Mp 13 Ventures, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Michael D Blaszyk director C/O NANTKWEST, INC., 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
John Owen Brennan director C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Wesley Clark director C/O ARGYLE SECURITY ACQUISITION CORP., 200 CONCORD PLAZA, SUITE 700, SAN ANTONIO TX 78216
Regan J Lauer officer: Chief Accounting Officer 4250 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Richard Adcock officer: Chief Executive Officer C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Linda Maxwell director 1040 SPRING STREET, SILVER SPRING NC 27709
Christobel Selecky director C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David C. Sachs officer: Chief Financial Officer C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Frederick W Driscoll director

ImmunityBio (ImmunityBio) Headlines

From GuruFocus